Professor of Clinical Neurological Surgery, UCSF School of Medicine
Neurology
Dr. Nicholas A. Butowski, MD
|
|
Give Review
Nicholas A. Butowski works in the field of Neurology. He graduated from University of Illinois College of Medicine. He has 4 awards "Essential Core Teaching Award", "CMS Meaningful Use Stage 1 Certification", "Voice of the Patient Award" and "General Assembly State Scholarship". Nicholas A. Butowski is a published doctor and has 48 publications published. The lastest was: 'Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- In Reply: Survival With Glioblastoma Multiforme and the Timing of Chemoradiation.
- Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.
- Central Nervous System Cancers, Version 1.2015.
- NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification.
- Central Nervous system cancers, version 2.2014.
- Familial Gliomas: cases in two pairs of brothers.
- Clinical Practice Experience with NovoTTF-100A™ System for Glioblastoma: the Patient Registry Dataset (PRiDe).
- Phase II Trial of 7days on/7 days off temozolmide for recurrent high-grade glioma.
- A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
- Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
- Disseminated progression of glioblastoma after treatment with bevacizumab.
- Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
- Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
- Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein.
- Endpoints for clinical trials and revised assessment in neuro-oncology.
- Neurosurgical management and prognosis of patients with glioblastoma that progress during bevacizumab treatment.
- Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
- Impact of bevacizumab chemotherapy on craniotomy wound healing.
- Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium St...
- Diagnosis and treatment of recurrent high-grade Astrocytoma.
- Glial Tumors: the current state of scientific knowledge.
- Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme.
- Medical management of Brain metastases.
- Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme an...
- Conditional Probability of Survival in Patients With Newly Diagnosed Glioblastoma.
- General and neurological complications of targeted therapy.
- Identifying the needs of Brain tumor patients and their caregivers.
- Central Nervous system cancers.
- Anti-angiogenic therapy in glioma.
- Recent advances in therapy for glioblastoma.
- Therapeutic advances for glioblastoma multiforme: current status and future prospects.
- A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
- Small molecule and monoclonal antibody therapies in neurooncology.
- GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.
- Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
- Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme.
- Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy.
- Quality of life in low-grade glioma patients receiving temozolomide.
- A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NAB...
- A North American Brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
- Preoperative prognostic classification System for hemispheric low-grade gliomas in adults.
- Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
- Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma.
- Immunostimulants for malignant Gliomas.
- Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
- Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
Schools
University Of Illinois College Of Medicine Chicago
University Ca Sf School Of Med
Conditions Treated
- Ataxia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Aneurysm
- Cerebral Hemorrhage
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- Essential Core Teaching Award
- CMS Meaningful Use Stage 1 Certification
- Voice of the Patient Award
- General Assembly State Scholarship
Education
-
UCSF Medical Center -
McGaw Medical Center of Northwestern University -
University of Illinois College of Medicine
Hospital
-
San Francisco VA Medical Center -
UCSF Medical Center -
Ronald Reagan UCLA Medical Center
Drug Facts
| NPI NUMBER | 1184681009 | |
| NPPES Provider LastName | BUTOWSKI | |
| NPPES Provider FirstName | NICHOLAS | |
| NPPES Provider ZIPCode | 941432202 | |
| NPPES Provider State | CA | |
| Specialty Description | Neurology | |
| Total Claim Count | 86.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184681009 |
| Last Name Of The Provider | BUTOWSKI |
| First Name Of The Provider | NICHOLAS |
| View All |
Similar Doctors
|
|
Dr. Joey D. English, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary M. Abrams, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Hannah C. Glass, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Georges Naasan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley B. Prusiner, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Borina Dramov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elan L. Guterman, MD |
|
|
Dr. Katherine T. Hamilton, MD |
|
|
Dr. Till Sprenger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy R. Tso, MD |
|
|
Dr. Michael R. Wilson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Paul Dellemijn |